Generic Competition to 2009: Industry Research Report

Generic Competition to 2009

Published Date: September 2005

Published By: Urch Publishing

Page Count: 94

Order Code: R410-123

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Description

Table of Contents

Search Inside
this Report

Similar
Products

Executive Summary
1. The Impact of Patent Expiries 2005-2009: Introduction; Patent Expiry by date; Major Companies; Major Generic Companies; Europe; Sandoz; Merck KGaA; Schwarz Pharma; North America; Israel & India
2. Historical and Legal Context: Impact of generics on revenue; National factors; Prozac; Patent Regulations; Europe; United States; Hatch-Waxmax; ANDA process
3. Generic Biotechnology Products: Introduction; Procrit/Epogen; NeoRecormon/Epogin; Interferon beta products; Neupogen/Neutrogin; Approval process
4. Expiries in 2005: Overview; Major Patent Expiries In Europe; Major patent expiries in the United States; Potential revenue loss; Advair/Seretide; glimepiride (Amaryl); clarithromycin (Biaxin/Klacid); cefprozil (Cefzil/Procef); fentanyl (Duragesic); enoxaparin (Lovenox); clopidogrel (Plavix); pravastatin (Pravachol/ Mevalotin); ceftriaxone (Rocephin); azithromycin (Zithromax)
5. Expiries in 2006: Overview; Major Patent Expiries In Europe; Major patent expiries in the United States; Potential revenue loss; zolpidem tartrate (Ambien/Stilnox/Myslee); carvedilol (Coreg/Dilatrend); tersbinafine (Lamisil); finasteride (Proscar); simvastatin (Zocor); ondansetron (Zofran); sertraline (Zoloft)
6. Expiries in 2007: Overview; Major Patent Expiries In Europe; Major patent expiries in the United States; Potential revenue loss; irinotecan (Camptosar, Campto, Topotecin); sumatriptan (Imigran/Imitrex); granisetron hydrochloride (Kytril); esomeprazole (Nexium); amlodipine besylate (Norvasc); paroxetine hydrochloride (Paxil/Seroxat); budesonide (Pulmicort)*; risperidone (Risperdal); cetirizine (Zyrtec)
7. Expiries in 2008: Overview; Major Patent Expiries In Europe; Major patent expiries in the United States; Potential revenue loss; bicalutamide (Casodex); ramipril (Delix/Tritace); divalproex sodium (Depakote/Valcote); venlafaxine (Effexor); alendronate (Fosamax/Bonalon); lamotrigine (Lamictal); meloxicam (Mobic); tacrolimus (Prograf and Protopic); salmeterol (Serevent)
8. Expiries in 2009: Introduction; Major Patent Expiries In Europe; Major patent expiries in the United States; Potential revenue loss; adenosine injection (Adenoscan/Adenocard); mycophenolate mofetil (Cellcept); tamsulosin (Flomax, Omnic, Harnal); levetiracetam (Keppra); escitalopram (Lexapro/Cipralex); pantoprazole (Protonix); micronized fenofibrate (TriCor/Lipanthyl); orlistat (Xenical)
List of Figures: Figure 2.1 2004 revenues in the United States for drugs going off patent in the year indicated.; Figure 2.2 Number of potential generic market entries in the United States 2005 to 2009; Figure 2.3 Number of potential generic market entries in the France, Germany and the United Kingdom 2005 to 2009; Figure 2.4 Number of chemical entities likely to be exposed to generic competition between 2005 and 2009.; Figure 2.5 Potential revenue loss (of 2004 U.S. sales) to generic competition for the top 20 pharmaceutical companies plus Forest and King.; Figure 3.1 US sales of Prozac and generic fluoxetine 2000-2004.; Table 3.1 Leading Biotechnology therapeutics showing global reported sales for 2003 and 2004.; Table 8.1 Major drugs whose patents expire in France, Gemany and/or the United Kingdom in 2009.
List of Tables: Table 4.1 Major drugs whose patents expire in France, Germany and/or the United Kingdom in 2005.; Table 4.2 Major Drugs whose patent protection and marketing exclusivity expires in the United States in 2005.; Table 5.1 Major drugs whose patents expire in France, Gemany and/or the United Kingdom in 2006.; Table 5.2 Major Drugs whose patent protection and marketing exclusivity expires in the United States in 2006; Table 6.1 Major drugs whose patents expire in France, Gemany and/or the United Kingdom in 2007.; Table 6.2 Major Drugs whose patent protection and marketing exclusivity expires in the United States in 2007.; Table 7.1 Major drugs whose patents expire in France, Gemany and/or the United Kingdom in 2008.; Table 7.2 Major Drugs whose patent protection and marketing exclusivity expires in the United States in 2008.; Table 8.2 Major Drugs whose patent protection and marketing exclusivity expires in the United States in 2009.